Serum Based Marker untuk Pemeriksaan Laboratorium Karsinoma Mamae
DOI:
https://doi.org/10.56260/sciena.v3i2.132Keywords:
Breast cancer, recurrence, serum based markerAbstract
Kanker merupakan masalah kesehatan utama di dunia dan salah satu penyebab penting morbiditas dan mortalitas pada anak dan dewasa. Kanker disebabkan oleh proliferasi sel yang tidak terkontrol dan penyebaran klon sel ganas. Karsinoma mammae adalah tumor ganas yang berasal dari jaringan payudara dan merupakan kanker yang paling banyak mengenai wanita, sekitar satu juta kasus baru didiagnosis setiap tahunnya. Penanda tumor adalah suatu senyawa yang dapat diukur dalam darah, jaringan tumor atau cairan tubuh lainnya yang digunakan untuk membantu deteksi kanker dan atau terapinya. Penanda tumor karsinoma mammae dibagi menjadi tiga yaitu penanda yang terdapat pada serum (serum based marker), penanda yang terdapat pada jaringan (tissue based marker), dan penanda genetik (genetic marker). Serum based marker di antaranya MUC-1 (CA 15.3, CA 27.29), CEA, sitokeratin (TPA, TPS, CYFRA 21-1), sHER-2 dan proteomic. Pemeriksaan serum based marker banyak dilakukan karena lebih ekonomis dan tidak invasif. European Group for Tumor Markers dan NACB menyatakan bahwa pengukuran penanda tumor secara berkala penting untuk memantau pasien karsinoma mammae dalam rangka deteksi awal terjadinya rekurensi, karena penanda tumor sering meningkat sebelum munculnya tanda klinis atau radiologis. Pemeriksaan serial penanda tumor juga berguna untuk menentukan prognosis dan pemantauan terapi.
References
. American Cancer Society. Breast Cancer. Published online 2014. www.m.cancer.org
. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54(12). doi:10.1373/clinchem.2008.105601
. Meisner ALW, Houman Fekrazad M, Royce ME. Breast Disease: Benign and Malignant. Med Clin North Am. 2008;92(5):1115-1141. doi:10.1016/j.mcna.2008.04.003
. Mirabelli P, Incoronato M. Usefulness of traditional serum biomarkers for management of breast cancer patients. Biomed Res Int. 2013;2013. doi:10.1155/2013/685641
. Duffy J. The Clinical Value of Tumour Markers in Breast Cancer. Eur Oncol Haematol. 2006;(1):23. doi:10.17925/eoh.2006.0.1.23
. Vaidyanathan K, Vasudevan DM. Organ specific tumor markers: What’s new? Indian J Clin Biochem. 2012;27(2):110-120. doi:10.1007/s12291-011-0173-8
. American Cancer Society. Tumor Markers. Published online 2013. www.m.cancer.org
. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002;71(6):907-920. doi:10.1189/jlb.71.6.907
. Mak TW, Saunders ME. Cancer and The Immune System. In: The Immune Response: Basic and Clinical Principles 1st Edition. First. Elsevier; 2006:502-524.
. Nair R, Johnson J. A Dictionary to Tumor Markers and The Methods of Estimation, Advanced Biotech. Adv Biotech. Published online 2008:22-32.
. Molina R, Barak V, Van Dalen A, et al. Tumor markers in breast cancer - European group on tumor markers recommendations. Tumor Biol. 2005;26(6):281-293. doi:10.1159/000089260
. Suarfi, A. S., Anggraini, D., & Nurwiyeni, N. (2019). Gambaran Histopatologi Tumor Ganas Payudara di Laboratorium Patologi Anatomi RSUP M. Djamil Padang Tahun 2017. Health and Medical Journal, 1(1), 07-14.
. Kuespert K, Pils S, Hauck CR. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol. 2006;18(5):565-571. doi:10.1016/j.ceb.2006.08.008
. Abbas A, Lichtman A, Pillai S. Cellular and Molecular Immunology. Seventh. Elsevier Saunders; 2012.
. Blumenthal RD, Hansen HJ, Goldenberg DM. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen). Cancer Res. 2005;65(19):8809-8817. doi:10.1158/0008-5472.CAN-05-0420
. Duffy MJ. Serum tumor markers in breast cancer: Are they of clinical value? Clin Chem. 2006;52(3):345-351. doi:10.1373/clinchem.2005.059832
. Singh R, Bandyopadhyay D. A target molecule for cancer therapy. Cancer Biol Ther. 2007;6(4):481-486. doi:10.4161/cbt.6.4.4201
. Gauchez AS, Ravanel N, Villemain D, et al. Evaluation of a manual ELISA kit for determination of HER2/neu in serum of breast cancer patients. Anticancer Res. 2008;28(5 B):3067-3073.
. Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem. 2004;37(7):529-540. doi:10.1016/j.clinbiochem.2004.05.009
. Ahn SK, Moon HG, Ko E, et al. Preoperative serum tissue polypeptide-specific antigen is a valuable prognostic marker in breast cancer. Int J Cancer. 2012;132(4):875-881. doi:10.1002/ijc.27727
. Nakata B, Takashima T, Ogawa Y, Ishikawa T, Hirakawa K. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer. 2004;91(5):873-878. doi:10.1038/sj.bjc.6602074
. Bluth M. High-Throughput Genomic and Proteomic Technologies in The Post Genomic Era. In: McPherson R, Pincus M, eds. Henry’s Clinical Diagnosis and Management by Laboratory Methods. 22nd ed. Elsevier Saunders; 2011:1470-1471.
. Kim BK, Lee JW, Park PJ, et al. The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res. 2009;11(2):1-12. doi:10.1186/bcr2247
. Le Naour F, Misek DE, Krause MC, et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res. 2001;7(11):3328-3335.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Donaliazarti
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
